iCast Covered Stent System
Atrium Medical Corp. · Decision date Aug 20, 2025
What did the FDA decide?
FDA records P120003/S010 as a supplement to PMA P120003, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 20, 2025.
FDA approval order statement
changes to the delivery system manufacturing process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 20, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P120003/S010
- Regulatory pathway
- PMA supplement
- Applicant
- Atrium Medical Corp.
- Product code
- PRL
- Decision code
- OK30
- Decision date
- Aug 20, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Iliac covered stent, arterial.
- Applicant
- Atrium Medical Corp.
- Product code
- PRL
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P120003/S010 received
Application receipt date recorded by FDA.
P120003/S010 · FDA decision
30-Day Notice
P120003/S011 · Related supplement
iCast Covered Stent System
P120003/S009 · Related supplement
iCast Covered Stent System
P120003/S007 · Related supplement
iCast Covered Stent System
Timeline entries are records held by MedtechLedger for P120003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
iCast Covered Stent SystemP120003/S011 | Atrium Medical Corp. | PMA supplement | Sep 12, 2025 | FDA |
iCast Covered Stent SystemP120003/S009 | Atrium Medical Corp. | PMA supplement | Dec 22, 2025 | FDA |
iCast Covered Stent SystemP120003/S007 | Atrium Medical Corp. | PMA supplement | May 13, 2026 | FDA |
Explore the linked device profile
Other records with product code PRL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA supplement | Oct 8, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Jun 16, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Feb 5, 2026 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Nov 24, 2025 | FDA | |
| W. L. Gore & Associates, Inc. | PMA supplement | Oct 17, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Atrium Medical Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5 Wentworth Dr., Hudson, NH, 03051
Sources and methodology
- Original FDA record: P120003/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




